Thanh bên bài viết

PDF
Ngày xuất bản: 28/07/2022
Ngày xuất bản Online: 07/09/2022
Số lượt xem tóm tắt: 173
Số lượt xem PDF: 188
DOI: https://doi.org/10.47972/vjcts.v38i.788
Số xuất bản
Tập 38
Chuyên mục
Bài báo
Trích dẫn bài báo
Binh, N. H. (2022). Result of surgical treatment for pulmonary metastasis from hepatocellularcarcinoma. Tạp chí Phẫu thuật Tim mạch và Lồng ngực Việt Nam, 38, 50-59. https://doi.org/10.47972/vjcts.v38i.788

Result of surgical treatment for pulmonary metastasis from hepatocellularcarcinoma

Binh Nguyen Hoang

Nội dung chính của bài viết

Tóm tắt

Objective: Evaluating result of surgical treatment, prognosis factors to survival time in pulmonary metastasis (PM) from Hepatocellular carcinoma (HCC) patients at Cho Ray hospital.
Method: A retrospective review of surgical treatment of PM from HCC patients at Cho Ray hospital from 11/2015 – 5/2020.
Results: Total 24 PM from HCC patients were surgical treatment. The mean tumor size is 2.7  1.1cm (range 1- 6 cm). The mean FDI (free disease interval) is 23.37  21.23 (2 – 108) month. Most of patients were thoracoscopic wedge resection of pulmonary metastasis. There was no mortality and major complication, 2 patients with seroma. Folow up, 7 patients died. The mean survival time 25.7  4.7 tháng (1- 46 tháng). The rate of 1 year, 2 years, 3 years overall survival is 86.5 %, 46.2% and 30.8 respectively.
Conclusion:  Surgical resection is a safe and effective treatment in selected patients with pulmonary metastases from HCC.The patients with previous resection of HCC have survival time longer than those with transdermal ablation. The patients with serumAFP level > 100 ng after HCC resection need to be screening chest CT Scans for PM

Chi tiết bài viết

Từ khóa

pulmonary metastasis (PM), hepatocellular carcinoma (HCC)

Tài liệu tham khảo

1. Chen YJ, Hsu HS, Hsieh CC et al: Pulmonary metastasectomy for hepato- cellular carcinoma. Chin Med Assoc, 2004; 67: 621–24
2. Gwak GY, Jung JO, Sung SW et al: Long-term survival after pulmonary met- astatectomy of hepatocellular carcinoma; treatment outcome or natural history? Hepatogastroenterology, 2004; 51: 1428–33
3. Hustinx R. PET imaging in assessing gastrointestinal tumors. Radiol Clin North Am 2004; 42: 1123-39,
4. Jang JW, Park YM, Bae SH, Choi JY, Yoon SK, Chang UI, Nam SW, Kim BS. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5- uorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol, 2004; 54: 415-420
5. Jong-Bum Kwon, Khun Park, Young-Du Kim, Jong-HeeSeo, Seok-Whan Moon, Deog- Gon Cho, Yong-Whan Kim, Dong-Goo Kim, Seung-Kew Yoon, Hyeon-Woo Lim.
Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: Analysis of prognostic factors. World J Gastroenterol, 2008 October 7;
14(37): 5717-5722
6. Kanda M, Tateishi R, Yoshida H et al: Extrahepatic metastasis of hepato-cellular carcinoma: incidence and risk factors. Liver Int, 2008; 28: 1256–63
7. Kuo SW, Chang YL, Huang PM et al: Prognostic factors for pulmonary metas- tasectomy in hepatocellular carcinoma.Ann Surg Oncol, 2007; 14: 992–97
8. McCormack P. Surgical resection of pulmonary metastases. Semin Surg Oncol, 1990; 6: 297-302
9. Yan-Ming Zhou* Xiao-Feng Zhang* FengYu
Xiao-Bin Liu Lu-Peng Wu BinLi, Jia-Mei Yang. Efficacy of Surgical Resection for Pulmonary Metastases from Hepatocellular
Carcinoma.Med Sci Monit, 2014; 20: 1544-1549